The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults
Clicks: 86
ID: 119884
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
25.5
/100
86 views
11 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #228 of 273 articles by views in the journal of clinical psychiatry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Aside from intramuscular injection, few rapidly acting pharmacotherapeutic treatments are available for acute agitation. This study examined the safety and tolerability of INP105, a drug-device combination product that allows nasal delivery of olanzapine.
| Reference Key |
shrewsbury2020thethe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Stephen B. Shrewsbury;Jasna Hocevar-Trnka;Kelsey H. Satterly;Karen L. Craig;Jason D. Lickliter;John Hoekman; |
| Journal | the journal of clinical psychiatry |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.